文献速递骨软组织肉瘤与黑色素瘤

MEK抑制剂司美替尼单药或联合紫杉醇治疗转移性葡萄膜黑色素瘤的三臂随机II期研究

A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
PubMed 文献 · Eur J Cancer · 2024-03-11

77例未接受过化疗的转移性葡萄膜黑色素瘤患者随机接受司美替尼单药或联合紫杉醇(联合组含中断或不中断司美替尼两臂,修正后合并分析)。联合组中位无进展生存期4.8个月 vs 单药组3.4个月(HR 0.62,90%CI 0.41-0.92,单侧P=0.022),客观缓解率14% vs 4%;中位总生存期9个月 vs 10个月(HR 0.98,90%CI 0.58-1.66,单侧P=0.469),无显著差异。联合组达到主要终点,但无进展生存期改善有限,不改变临床实践。

要点

  • 联合组中位无进展生存期4.8个月 vs 司美替尼单药组3.4个月(HR 0.62,90%CI 0.41-0.92,单侧P=0.022)。
  • 联合组客观缓解率14% vs 单药组4%。
  • 中位总生存期联合组9个月 vs 单药组10个月(HR 0.98,90%CI 0.58-1.66),无显著差异。

核心结论

  • 司美替尼联合紫杉醇达到主要终点,联合组无进展生存期较司美替尼单药组改善。
  • 总生存期无改善,无进展生存期改善有限,不改变临床实践。

研究设计与样本

  • 三臂随机II期研究,纳入77例未接受过化疗的转移性葡萄膜黑色素瘤患者。
  • 随机分配至司美替尼单药组、司美替尼联合紫杉醇组(紫杉醇前中断司美替尼两天)或司美替尼联合紫杉醇组(不中断司美替尼)。
  • 主要终点为无进展生存期;修正后联合两臂合并分析,样本量调整以检测风险比0.55,80%把握度,单侧5%显著性水平。

主要发现

  • 联合组中位无进展生存期4.8个月(95%CI 3.8-5.6) vs 司美替尼单药组3.4个月(95%CI 2.0-3.9),HR 0.62(90%CI 0.41-0.92),单侧P=0.022。
  • 联合组客观缓解率14% vs 单药组4%。
  • 联合组中位总生存期9个月 vs 单药组10个月,HR 0.98(90%CI 0.58-1.66),单侧P=0.469,无显著差异。
  • 毒性符合所用药物已知特征。

临床怎么用

  • 作者认为无进展生存期改善有限,不改变临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel. The primary endpoint was progression free survival (PFS). After amendment, the combination arms were combined for analysis and the sample size adjusted to detect a hazard ratio (HR): 0.55, 80% power at 1-sided 5% significance level. RESULTS: The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022). ORR was 14% and 4% in the combination and monotherapy arms respectively. Median OS was 9 months for the combination and was not significantly different from selumetinib alone (10 months) with HR of 0.98 [90% CI 0.58 - 1.66], 1-sided p-value = 0.469. Toxicity was in keeping with the known profiles of the agents involved. CONCLUSIONS: SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel. No improvement in OS was observed, and the modest improvement in PFS is not practice changing.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sacco JJ, Jackson R, Corrie P, et al. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Eur J Cancer. 2024. PMID: 38547774. doi:10.1016/j.ejca.2024.114009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。